nabu.science
MethodologyAboutContact

 

  • Snapshot
  • Key Claims
  • Strengths & Limitations
  • Commentary
  • From the Authors
  • Author Note / Field Feedback
  • Dimension breakdown
  • Impact Profile
Free · About 5 minutes
Report #NBU-E04FCE3A·Framework v5.13·Pipeline v0.4·Evaluated 19 Nov 2026·OECD: 3.3 Health sciences·Subfield: Clinical Neurology·Basis: Full text·Type: Observational cohort study

Prevalence of chronic traumatic encephalopathy at death in National Football League players: retrospective population based cohort study, 2008-21

2026·BMJ·10.1136/bmj-2026-100418 ↗

Primary claim

At minimum, nearly a quarter of all former NFL players who died during 2016-21 had CTE neuropathology at death.

Well-supported · 215 confirmed cases among 878 enumerated deaths establish the stated lower bound without assuming representative donation
In brief

Enumerated NFL deaths establish a 24.5% minimum CTE prevalence in 2016–21, but symptom-driven brain donation limits interpretation of the dementia association.

ReliabilityCaveats4 of 4 checks completeRead the 2 entries ↓
Likely to hold — the claim's weakest requirement is that the effect exists at all. Based on how the study was designed and conducted, not on statistics extracted from the paper. Experimental. Every point below is traceable to a quoted passage, but this forecast has not yet been validated against known replication outcomes.
Abstract

OBJECTIVES: To determine the range of possible prevalences of chronic traumatic encephalopathy (CTE) at death among National Football League (NFL) players and examine the association between CTE severity and risk of dementia. DESIGN: Retrospective population based cohort study. SETTING: NFL players from the era of hard-shell helmets (post-1949) in the US, including brain donors to the UNITE (Understanding Neurologic Injury and Traumatic Encephalopathy) and UCSF ADRC (University of California, San Francisco Alzheimer's Disease Research Center) brain banks. PARTICIPANTS: 1712 former NFL players who died during 2008-21, of whom 338 donated their brains for neuropathological evaluation. Personal information and causes of death according to the National Death Index (NDI) were obtained for all NFL players who died during the study period. Neuropathologists masked to clinical and playing histories assessed postmortem CTE diagnosis and stage IV CTE. Clinicians, masked to neuropathological status, reviewed donors' medical records and informant based clinical histories, to adjudicate a dementia diagnosis. MAIN OUTCOME MEASURES: The main outcome measures were the minimum (number of donors with CTE/total number of NFL deaths) and maximum (1-(number of donors without CTE/total number of NFL deaths)) CTE prevalence at death during the study period and the six years (2016-21) when brain donation was most frequent. To account for selection pressure of brain donation status, inverse probability weighting was used to estimate the association between stage IV CTE and study clinician diagnosed dementia. RESULTS: Among 1712 NFL players who died, 338 (19.7%) players' brains were studied, 315 (93.2%) of whom had a diagnosis of CTE; thus, among all 1712 NFL players who died, the possible CTE prevalence at death ranged between 18.5% and 98.7%. The possible prevalence at death during 2016 to 2021, when brain donation was most frequent, ranged between 24.5% and 97.7%. Among brain donors, 104 (30.8%) had stage IV CTE, 202 (59.8%) had study clinician diagnosed dementia (dementia onset: 63.4 years, standard deviation (SD) 12.5; death: 73.1 years, SD 10.5), and 63 (18.6%) had neurodegenerative disease listed as primary cause of death. In donors, stage IV CTE was associated with study clinician diagnosed dementia (risk ratio 1.44, 95% confidence interval 1.16 to 1.78; P<0.001). Only 40.6% of donors (n=82) with study clinician diagnosed dementia had neurodegenerative disease listed as the primary or secondary cause of death. CONCLUSIONS: At minimum, nearly a quarter of all former NFL players who died during 2016-21 had CTE neuropathology at death. Among NFL player brain donors, dementia diagnosed based on records before death was common and associated with stage IV CTE.

Key Claims

Primary finding · Well-supported

At minimum, nearly a quarter of all former NFL players who died during 2016-21 had CTE neuropathology at death.

Likely to hold — the claim's weakest requirement is that the effect exists at all. Based on how the study was designed and conducted, not on statistics extracted from the paper. Experimental. Every point below is traceable to a quoted passage, but this forecast has not yet been validated against known replication outcomes.

215 confirmed cases among 878 enumerated deaths establish the stated lower bound without assuming representative donation

Abstract, Conclusions
Quote verified
Secondary · Tentative

In [NFL player brain] donors, stage IV CTE was associated with study clinician diagnosed dementia (risk ratio 1.44, 95% confidence interval 1.16 to 1.78; P<0.001).

symptom-driven donation, retrospective dementia assessment, and unadjusted co-pathology leave material uncertainty despite donor-restricted wording

Abstract, Results; Table 3
Quote verified
Secondary · Well-supported

Only 40.6% of [NFL player brain] donors (n=82) with study clinician diagnosed dementia had neurodegenerative disease listed as the primary or secondary cause of death [on death certificates].

direct comparison of 82 death-certificate records with 202 clinically adjudicated donor dementia cases

Abstract, Results; Table 1
Quote verified
Secondary · Tentative

NFL players have a higher prevalence of CTE at death than has been previously shown in multiple community based studies.

selected community-donor proportions do not identify the source-population prevalence needed for this population comparison

Conclusions
Quote verified

Derived from the full evaluation — not a separate score.

Strengths · Limitations

Strengths

#contribution

Enumerated deaths anchor a defensible minimum

The 215 confirmed CTE cases among 878 NFL deaths in 2016–21 establish a 24.5% lower bound without requiring brain donors to represent all decedents.

↳ Results, Extrapolating the prevalence of CTE at death

#methodological rigour

Masked assessments and alternative analytical specifications

Neuropathologists were masked to clinical histories, and clinicians adjudicated dementia without neuropathological results. Table 3 compares weighted, age-adjusted, and unadjusted specifications.

↳ Methods, Collection of clinical data and Neuropathological assessment; Table 3

#contribution

Death certificates compared with clinical adjudication

The donor-level comparison shows that only 82 of 202 clinically adjudicated dementia cases had neurodegenerative disease recorded as a primary or secondary cause of death.

↳ Abstract, Results; Table 1

Limitations

#methodological rigour

Donor association remains vulnerable to selection

Weighting cannot account directly for unobserved symptoms in non-donors, and the dementia regressions do not adjust for the co-occurring neurodegenerative pathologies concentrated in stage IV donors. These limitations leave the association's magnitude uncertain.

↳ Methods, Statistical analysis; Tables 2–3; Discussion, Strengths and limitations

#reporting

Population comparison exceeds the available evidence

The Conclusions compare NFL prevalence with community studies whose reported figures are selected donor proportions. That contrast does not establish the corresponding difference between source-population prevalences.

↳ Introduction; Conclusions

#positioning

Recall limitation is acknowledged then dismissed

The limitations section explains how differential informant sensitivity could inflate the association, then argues that masking excludes recall as an explanation. Masking to the final diagnosis does not eliminate the differential suspicion and symptom ascertainment already described.

↳ Discussion, Strengths and limitations, informant recall paragraph

Does this match your read? Add your assessment ↓

Nabu Commentary

The 2016–21 minimum prevalence is directly supported by confirmed cases within an enumerated decedent cohort, and the death-certificate comparison adds a distinct descriptive contribution. Masked assessments and alternative models strengthen execution, but weighting cannot observe symptom-driven donation and the association models omit co-occurring neurodegenerative pathologies. The Conclusions overextend the comparison with community-donor studies, while the recall-bias discussion dismisses a mechanism it has already acknowledged. Numerical and denominator reporting issues warrant clarification without overturning the 2016–21 lower bound.

Evaluate another paper

Free · About 5 minutes · Research preview

Author Note / Field Feedback

Nabu’s assessment, alongside the field’s view.

Are you an author of this paper?

Dimension breakdown

Evidence Score

Out of 5
012345
3.3±0.2

Contribution
3.7

The expanded, enumerated decedent cohort strengthens the minimum-prevalence estimate and adds a direct comparison between clinical dementia adjudication and death certificates. The advance extends existing bounding and donor-association work rather than identifying an exact population prevalence.

Introduction; Results, Extrapolating the prevalence of CTE at death; Table 1
Methodological Rigour
3.2

Masked pathology and clinical adjudication, cohort-based prevalence bounds, weighting, and sensitivity analyses support the design. Unobserved symptom-driven donation, retrospective clinical information, unadjusted co-pathology, and unresolved reporting issues leave meaningful uncertainty about the association's magnitude.

Methods, Collection of clinical data and Statistical analysis; Tables 2–3
Reporting
3.5

The lower-bound calculation and donor-restricted association are generally distinguishable. The concluding population comparison exceeds what selected community-donor proportions establish, while numerical and denominator slips interrupt otherwise followable reporting.

Abstract; Results; Conclusions
Positioning
2.8

The literature discussion engages community cohorts, specialist brain banks, prior bounds, and death-certificate studies. The recall-bias discussion nevertheless dismisses a differential-ascertainment mechanism that it has just acknowledged, limiting the execution of its otherwise substantive limitations analysis.

Introduction; Discussion, Strengths and limitations

Reliability

Caveats4 of 4 checks


Results checkNoted
  • "analyses without inverse probability weighting examining the relation between dementia and stage IV CTE (1.85, 1.77 to 1.94; P<0.001)" (Results, Dementia and clinical impairment underlying stage IV CTE among donors, unweighted RR) vs "94 of 104 (90.4%) of those with stage IV CTE" (Results, Dementia and clinical impairment underlying stage IV CTE among donors). Ignoring missing outcomes and imputation, 94/104 versus 108/234 gives RR approximately 1.96 and a conventional 95% interval approximately 1.68–2.28, so the fitted imputed interval cannot be reconstructed exactly. The effect on the result is unclear.
Reporting and transparencyNoted

The Discussion refers to an IPW prevalence point estimate not presented in the Results. Ethics approval, competing interests, and request-based data access are declared.

Conflict of interest: declared · Ethics approval: declared · Data availability: declared

Reference IntegrityClean

57 references in manuscript 56 of 56 checkable references found in an index 1 have no canonical index record — counted, but not index-checkable 1 mistyped DOI matched to the cited work by its details 1 reference confirmed by manual review

References not verified automatically are resolved manually within 24 hours.

Post-Publication RecordClean

No retraction or expression of concern found in Crossref (includes Retraction Watch).

Last checked: 19 Nov 2026

Sources: Crossref (incl. Retraction Watch) ✓

Impact Profile

Impact areaHealth · Neurological · Alzheimer's disease and other dementias
Type of advanceEmpirical
Route to useSuggested
AdvanceExtends
BeneficiariesLarge
CitationsToo early
Policy · patentNot yet traced
ReachedNot reachedNot assessable or unverified
ReadinessValidated
Foundational
Controlled
Piloted
Validated
Implementable
FoundationalImplementable

The prevalence claim is measured directly in real-world population data from a fully enumerated cohort of NFL decedents, with masked neuropathological assessment across three brain bank sites.

From the paper
“provide targets for future research studies and policy recommendations”

The paper names policy recommendations as a possible use of its own data but identifies no actor, organisation, or decision that would apply the findings.

Pathway

Public health officials and sports governing bodies could use these prevalence estimates to motivate and target head-impact reduction policies and brain-health surveillance in contact sports.

Barrier

CTE cannot be definitively diagnosed in living people, so these postmortem prevalence data cannot yet guide diagnosis, prevention, or treatment decisions for living athletes.

Evaluated 19 Nov 2026 · GBD 2023 · glm_v1_3_3 · impact_profile_v1_3_3

Report an issue →

AI-generated, human-governed. Something look off? Contact us to request a review.

Keep reading

Related evaluations

Other papers Nabu has evaluated blind, starting with the same field.

  1. Advancing biomarker development for chronic traumatic encephalopathy: Summary and recommendations from the 2025 Leon Thal Summit

    Bernick, Kleven, Alosco, et al. · 2026 · Basic medicine

    Primary claim

    There is no validated fluid biomarker for CTE.

    Supported
    Evidence Score
    3.4±0.2
    Reliability
    No concerns
  2. Traumatic brain injury and risk of early-onset dementia: A population-based cohort study

    Saravanan, Giorgio, Lakomski, et al. · 2026 · Clinical medicine

    Primary claim

    TBI was associated with higher risk of both EOD (HR: 4.06 [95% confidence interval: 3.13, 5.26]) and LOD (HR: 2.51 [2.31, 2.72]

    Supported
    Evidence Score
    3.5±0.2
    Reliability
    Caveats
  3. Cognitive, biomarker, and neuroimaging indices associated with traumatic encephalopathy syndrome across two independent athlete cohorts

    Conway Kleven, Chien, Surwill, et al. · 2026 · Clinical medicine

    Primary claim

    TES in RHI-exposed athletes was associated with a convergent clinicobiological profile across two independent cohorts.

    Tentative
    Evidence Score
    3.2±0.2
    Reliability
    Caveats

How the rubric works →